Announcements Trials
Browse Landscape

Status

Completed 71Recruiting 17Terminated 14Active not recruiting 14Unknown 9Withdrawn 8Not yet recruiting 2Suspended 1No longer available 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Hodgkin Disease 1Hematologic Diseases 1

Interventions

fludarabine phosphate 3venetoclax 2navitoclax 2fludarabine 2zanubrutinib 1sugemalimab 1plerixafor 1nilotinib 1midostaurin 1loncastuximab tesirine 1eryaspase 1ceritinib 1asparaginase erwinia chrysanthemi recombinant 1Whole-Body Irradiation 1Tacrolimus 1Mycophenolic Acid 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Brentuximab Vedotin 1Bone Marrow Transplantation 1Bendamustine Hydrochloride 1Asparaginase 1AP 1903 reagent 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × Brentuximab Vedotin × Lymphoid × Clear all
NCT01196208 2020-09-21

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Seagen Inc.

No longer available
DermatologicLymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡